6）Furukawa A, Tamura Y, Taniguchi H, Kawamura A, Nagase S, Hayashi A, et al. Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors. J Cardiol 2023; 81(1): 63-7.7）Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the european Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J 2013; 34(33): 2636-48.8）Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer 2016; 4: 13.9）Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 2020; 41(18): 1733-43.1241）Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016; 375(18): 1749-55.2）Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncology. 2018; 19(12): 1579-89.3）Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek S, Asnani A, et al. Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis. circulation 2021; 144(18): 1521-3.4）Tamura Y, Tamura Y, Taniguchi H, Imanaka-Yoshida K. Acute myocarditis after discontinuation of immune checkpoint inhibitor therapy. Circ J 2022 Oct 29. doi: 10.1253/circ. CJ-22-0613.5）Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc 2020; 9(2): e013757.文 献
元のページ ../index.html#138